

**TO DETERMINE THE PREVALENCE OF ASPIRIN RESISTANCE AND/OR  
PLATELET HYPERSENSITIVITY AS DETERMINED BY PLATELET  
AGGREGOMETRY IN CAUCASIAN PATIENTS WHO HAVE SUFFERED ONE  
OR MORE ATHEROTHROMBOTIC CEREBRO-VASCULAR ACCIDENTS  
(CVAS) AND/OR TRANSIENT ISCHAEMIC ATTACKS (TIAS) AS COMPARED  
WITH CONTROL SUBJECTS.**

Dr Penelope Lizetta Bernstein

A research report submitted to the Faculty of Health Sciences, University of the  
Witwatersrand, Johannesburg, in partial fulfilment of the requirements for the degree of

Master of Medicine

in

the branch of Molecular Medicine and Haematology

Johannesburg, 2009

## **DECLARATION**

I, Penelope Lizetta Bernstein declare that this research report is my own unaided work. It is being submitted for the degree of Master of Medicine in the branch of Molecular Medicine and Haematology at the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at this or any other University.

.....

..... day of ....., 2009

## **DEDICATION**

To my husband, Jeremy and my mother, Irene for their interest, support and encouragement.

To my grandparents, Professor Ralph and Dr Mary Bernstein, for instilling in me a love for medicine and academia.

## **PUBLICATIONS AND PRESENTATIONS ARISING FROM THIS STUDY**

Bernstein PL, Jacobson BF, Connor MD, Becker PJ. Aspirin resistance in South African Caucasian patients with thrombotic cerebrovascular events. *J Neuro Sci* 2009; 277: 80-82.

Poster presentation at the South African Society of Thrombosis and Haemostasis Annual Conference, November 2006.

## ABSTRACT

**Objective:** Stroke is the second most common cause of death in most countries.<sup>1</sup> In South Africa, which has a population undergoing demographic and epidemiological transition, stroke is the third most common cause of death.<sup>2</sup> Platelet response to therapeutic doses is not uniform, although aspirin remains an essential part of treatment. Some patients exhibit aspirin resistance and develop secondary thrombotic events. It was decided to determine the prevalence of aspirin resistance and/or platelet hypersensitivity, as determined by platelet aggregometry, in sixty Caucasian patients who have suffered one or more strokes and/or Transient Ischaemic Attacks (TIAs) as compared with sixty control subjects.

**Methods:** Aspirin resistance was determined by platelet aggregation (>20%) to one or more of the four agonists, namely arachidonic acid (1.5mM), adrenaline (0.05µg/ml), collagen (0.2µg/ml) or ADP ( $0.1 \times 10^{-5}$  M).

**Results:** Two patients demonstrated 'complete aspirin resistance' (non-responder to aspirin) with resistance to arachidonic acid (high concentration) noted. Three patients demonstrated 'partial aspirin resistance' (semi-responder to aspirin). One control subject showed 'complete aspirin resistance'. There is a 1.67% chance of a control subject being resistant to aspirin in a general South African Caucasian population. A history of prior stroke or transient ischaemic attack was associated with a statistically significant increase in risk of aspirin resistance with an odds ratio of 5.36.

**Conclusion:** These results essentially concur with those of the studied literature in showing an 8.3% prevalence (statistically significant) of aspirin resistance (complete and partial) in South

African Caucasian patients with previous atherothrombotic cerebrovascular events i.e.CVAs and/or TIAs. The current study shows an increased prevalence of aspirin resistance in people who have had prior strokes / TIAs and raises the question whether people who have had these events are somehow predisposed to vascular events or indeed recurrent vascular events.

‘Aspirin resistant’ patients or ‘poor responders’ to aspirin must be considered at heightened risk of atherothrombotic events and laboratory monitoring of antiplatelet therapy may become clinically useful.

## **ACKNOWLEDGEMENTS**

1. Many thanks to Professor Barry Jacobson, Head of Clinical Haematology, Department of Molecular Medicine and Haematology, National Health Laboratory Service (NHLS) and the Faculty of Health Sciences, University of the Witwatersrand, for his continuous support in this project. His enthusiasm, patience, effort and sound practical advice have been an inspiration to me both in this research report, international publication and in my daily dealings with Haematology (both in the laboratory and with regard to patients).

2. I wish to thank Professor Myles Connor, previously a consultant Neurologist from the Department of Neurosciences, Faculty of Health Sciences, University of the Witwatersrand, for his insight, guidance and assistance with the study and the international publication.

3. Many thanks also to Professor Piet Becker of the Biostatistics Unit, Medical Research Council of South Africa (SAMRC) and School of Therapeutic Sciences, University of the Witwatersrand, for his help with the statistical analysis of the data.

4. The source of funding was from the South African Society of Thrombosis and Haemostasis (SASTH) Research Fund.

<b>TABLE OF CONTENTS</b>	<b>PAGE</b>
DECLARATION	ii
DEDICATION	iii
PUBLICATIONS AND PRESENTATIONS ARISING FROM THIS STUDY	iv
ABSTRACT	v
ACKNOWLEDGEMENTS	vii
TABLE OF CONTENTS	viii
LIST OF TABLES	xi
LIST OF FIGURES	xii
ABBREVIATIONS	xiii
<b>1. INTRODUCTION AND LITERATURE REVIEW</b>	
1.1 The haemostatic response	1
1.1.1 Vasoconstriction	1
1.1.2 Primary haemostasis and platelet reactions	2
1.1.3 Stabilisation of the platelet plug by fibrin	4
1.2 Stroke	5
1.3 Antiplatelet agents	7
1.4 Aspirin	10
1.5 Aspirin resistance	11
1.6 Platelet aggregometry testing	13



<b>2.</b>	<b>STUDY OBJECTIVE</b>	16
<b>3.</b>	<b>STUDY POPULATIONS, MATERIALS AND METHODS</b>	
3.1	Case selection	16
3.2	Control selection	17
3.3	Laboratory methods	18
3.3.1	Principle	18
3.3.2	Instrument description	18
3.3.3	Patient preparation and specimen collection	20
3.3.4	Preparation of platelets	20
3.3.5	Aggregating agents (agonists)	21
3.3.6	Stepwise procedure and interpretation of platelet aggregation curves	22
3.3.7	Comments and limitations	23
3.4	Statistical analysis	24
3.5	Ethics	25
<b>4.</b>	<b>RESULTS</b>	
4.1	Patient results	26
4.2	Control results	28
<b>5.</b>	<b>DISCUSSION</b>	29

<b>6.</b>	<b>CONCLUSION</b>	35
<b>7.</b>	<b>APPENDICES</b>	
	Appendix A: Copy of the Ethics Clearance Certificate	36
	Appendix B: Results on which statistical analysis was performed (raw data).	37
<b>8.</b>	<b>REFERENCES</b>	40

## LIST OF TABLES

<b>Table</b>		<b>Page</b>
Table 3.1	High and low concentrations of agonists.	22

## LIST OF FIGURES

<b>Figure</b>		<b>Page</b>
Figure 1.1	The interaction of blood vessels, blood coagulation and platelet in haemostasis.	2
Figure 1.2	Primary haemostasis.	3
Figure 1.3	The production of prostacyclin and thromboxane.	4
Figure 1.4	Sites of action of antiplatelet drugs.	12
Figure 3.1	APACT 2 ON Helena Aggregometer <sup>TM</sup> .	19
Figure 3.2	APACT 2 ON Helena Aggregometer <sup>TM</sup> - Top View.	19
Figure 3.3	Platelet aggregation studies.	21
Figure 4.1	Trace from a patient with ‘partial aspirin resistance’.	27
Figure 4.2	Trace from a control subject with ‘complete aspirin resistance’.	28

## ABBREVIATIONS

AA	Arachidonic Acid
ADP	Adenosine Diphosphate
AMP	Adenosine Monophosphate
APACT2	Automated Platelet Aggregation
ATP	Adenosine Triphosphate
Ca <sup>2+</sup>	Calcium
cAMP	cyclic Adenosine Monophosphate
CI	Confidence Interval
COX	Cyclooxygenase
CT	Computed Tomography
CVA	Cerebro-Vascular Accident
FBC	Full Blood Count
GP	Glycoprotein
HIV	Human Immunodeficiency Virus
LTA	Light Transmission Aggregometry
MI	Myocardial Infarct
MRI	Magnetic Resonance Imaging
NF-κB	Nuclear Factor kappa-light-chain-enhancer of activated B cells
NSAID	Non-Steroidal Anti-Inflammatory Drug
PGI <sub>2</sub>	Prostaglandin Inhibitor
PPI	Proton Pump Inhibitors
PPP	Platelet Poor Plasma

PRP	Platelet Rich Plasma
SOP	Standard Operating Procedure
TIA	Transient Ischaemic Attack
tPA	tissue Plasminogen Activator
TTP	Thrombotic Thrombocytopenic Purpura
TxA <sub>2</sub>	Thromboxane A <sub>2</sub>
TxB <sub>2</sub>	Thromboxane B <sub>2</sub>
VWF	Von Willebrand Factor